Telomir Pharmaceuticals Appoints Andriy Mushak as Fractional CFO
TELO sits 22% above its 52-week low of $1.05.
Summary
Telomir Pharmaceuticals announced the amicable departure of its CFO, Alan Weichselbaum, and appointed Andriy Mushak as its new fractional Chief Financial Officer, effective June 6, 2026, under a consulting agreement.
Key Events · Executive and Board Changes · TELO
-
CFO Departure
Alan Weichselbaum ceased serving as Chief Financial Officer, effective June 6, 2026. His departure was not due to any disagreement with the company.
-
New Fractional CFO Appointed
Andriy Mushak was appointed as the company's fractional Chief Financial Officer, effective June 6, 2026.
-
Consulting Agreement Details
Mr. Mushak will provide services through LMAM Consulting Group, LLC, for a monthly compensation of $6,000.
-
New CFO's Qualifications
Mr. Mushak is a Certified Public Accountant with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits, previously a Senior Manager at Baker Tilly US, LLP.
Analysis · TELO · Life Sciences
This filing details a significant change in Telomir Pharmaceuticals' financial leadership. The amicable departure of the previous CFO and the appointment of a highly qualified, albeit fractional, CFO suggests the company is adjusting its financial management structure. Given the company's recent 'going concern' warning and dilutive acquisition, this move could be interpreted as an effort to optimize costs and bring in specialized expertise to navigate its financial challenges. The fractional nature of the role and the relatively modest compensation indicate a strategic approach to financial oversight rather than a full-time executive hire.
At the time of this filing, TELO was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $88M. The 52-week trading range was $1.05 to $3.10. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.